38 C
Vientiane
Monday, April 28, 2025
spot_img
Home Blog Page 69

Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

HONG KONG, April 22, 2025 /PRNewswire/ — Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as “Venus Medtech” or the “Company”), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 (“the Year”), demonstrating significant improvements in profitability and operational discipline despite market challenges.

Key Financial Highlights

  1. Revenue: RMB471 million, with overseas revenue growing 13.53% YoY to RMB82.5 million.
  2. Adjusted non-IFRS EBITDA loss: Narrowed by 45.56% YoY to RMB254 million, reflecting stringent cost controls.
  3. Commercial profit: Surged 112.60% YoY to RMB97.7 million, with the commercial profit margin rising from 9.35% (2023) to 20.74%.
  4. Gross margin: Remained robust at 78.11%, underscoring pricing stability.

Facing a challenging landscape, Venus Medtech reinforced its leadership in China’s valvular therapy sector while achieving significant progress in operational efficiency and commercial profitability, mainly reflected in:

Cost Optimization

  • Sales expenses decreased by 18.44% YoY to RMB245 million, with the sales expense ratio decreasing from 61.15% (2023) to 52.05% through streamlined distributor management and accounts receivable reforms.
  • R&D expenses declined 35% YoY to RMB341 million, as the Company prioritized high-value pipeline projects, reducing R&D expense ratio from 106.83% to 72.46%.

Profitability Focus

  • The “Profitability-First” strategy drove a 112.60% increase in commercial profit (RMB97.7 million), while adjusted EBITDA losses halved (-45.56%), signaling sustainable financial traction.

Global Expansion and Maintain Domestic Leadership

In domestic markets, Venus MedTech focused on distributor channel development and penetrated tier-2 and tier-3 hospitals, securing its 1st position as China’s leading transcatheter aortic valve replacement (TAVR) provider.

  • Products are now used in over 650 hospitals nationwide.
  • The company participated in more than 90 third-party conferences and hosted over 100 proprietary events, engaging over 5,500 medical experts, and reaching more than 2 million online viewers.

Internationally, sales contributed 17.52% of total revenue (up from 14.79% in 2023). Growth was driven by Europe (+10.1%), Asia-Pacific (+16.6%), and Latin America (+38.6%). Venus Medtech expanded into 13 new countries, bringing its total global footprint to nearly 70 markets.

Key milestones included:

  • VenusP-Valve, the Company’s differentiated pulmonary valve product, entered 63 global markets, with new approvals in 12 countries/regions, including Canada, Australia, Singapore, Mexico.
  • VenusA Series products expanded to 15 countries/regions, with new approvals in countries including Russia, Thailand, Mexico, and Kazakhstan.

Innovation-Driven Pipeline Optimization for Sustainable Growth

Venus Medtech remains committed to innovation, advancing its “Four-Valve Strategy” for structural heart disease solutions. Key 2024 developments included:

Aortic Valve

  • Venus-PowerX completed its first patient enrollment in its global confirmatory trial (December 2024), with full China enrollment expected in 2025.
  • VenusA-Deluxe received China market approval in November 2024.

Pulmonary Valve

  • VenusP-Valve advanced its U.S. IDE (PROTEUS) pivotal study, with the first patient successfully implanted in June 2024.

Mitral/Tricuspid Valve

Cardiovalve’s trial in the treatment of tricuspid regurgitation enrolled nearly 120 patients across 30+ renowned cardiovascular centers in Germany, Italy, Spain, the UK, and Canada.

The Company also strengthened its intellectual property portfolio, holding 886 patents and applications (473 granted), including 402 filings in China (275 granted) and 460 overseas (435 granted).

Robust Clinical Evidence Demonstrates Long-Term Efficacy

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies for its registered clinical trials, generating outstanding data that validates the full spectrum of clinical benefits across its product lines. Key findings reported in the year include:

Cardiovalve TARGET CE Pivotal Study (Europe)

  • Immediate outcomes in the first 105 patients demonstrated 93.7% achieved ≤mild tricuspid regurgitation.
  • Early humanitarian use data in 20 patients with 100% severe or worse tricuspid regurgitation showed 90% reduced to ≤mild regurgitation at 30-day follow-up.

VenusP-Valve (5-year CE follow-up data)

  • No mortality or reinterventions, with right ventricular reverse remodeling confirmed via MRI at 6 months and durable functional improvement.
  • 94%+ of patients in NYHA Class I/II at 5 years, demonstrating sustained quality-of-life benefits.

“2024 was a transformative year for Venus Medtech,” said Lim Hou-Sen, CEO of Venus Medtech. “By prioritizing profitability, operational excellence, and global expansion, we have positioned the Company for sustainable growth. Moving forward, we will continue to innovate, optimize our commercial strategy, and deliver long-term value to patients and shareholders.”

About the company

Venus Medtech (2500.HK) was founded in 2009 and is headquartered in Hangzhou, China. It is an innovation-driven medical device company specializing in structural heart disease. The company’s product portfolio covers aortic, pulmonary, mitral, and tricuspid valve diseases, as well as surgical support products, forming a comprehensive pipeline. With global R&D centers in China, the United States, and Israel, Venus Medtech has established a worldwide network for research, production, marketing, and service. The company is committed to providing effective treatment solutions for life-threatening diseases.

China International Development Corporation has signed MOU with Carbontech Asia Pacific

Aimed at revolutionizing the Australian transportation industry

HONG KONG, April 22, 2025 /PRNewswire/ — China International Development Corporation Limited (“CIDC” or the “Company”, together with its subsidiaries, the “Group”; Stock Code: 0264 formed in collaboration with Flex Fuel Hydrogen Development Group Limited (“FFHD”) to announce the signing of a Memorandum of Understanding (“MOU”) with Star Allianz Capital Pty Ltd, Hon Chu Cheung and Flex Fuel Hydrogen Development Limited to acquire a 51% equity interest in Carbontech Asia Pacific Pty Ltd (the “Carbontech”), aimed at revolutionizing the Australian transportation industry.

With the Australian government’s new emissions reduction regulations set to take effect in 2025, the demand for effective carbon cleaning technologies has never been greater. These regulations will require transport companies to reduce their carbon footprints and improve fuel efficiency.

Under the MOU, CIDC proposes to purchase 51% of the equity interest in Carbontech. Carbontech located in Melbourne, is a leading provider of carbon cleaning technology for automotive engines. It specialize in using hydrogen-based and chemical additive technologies sourced from Flex Fuel, a French hydrogen manufacturing company.

To be the national and international market leader in carbon reduction solutions

Carbontech is poised to revolutionize engine decarbonization in Australia. In the short term, the company will establish a strong presence in Melbourne and major cities, educating transportation companies and aiming for top recognition in the Australian market. They will also introduce hydrogen and chemical additive technology to at least 100 Melbourne clients.

Over the medium term, expansion across all Australian states is planned, along with renting decarbonization machines to repair centers and introducing regular chemical additive sales, supported by mobile service units. The long-term vision is to become the market leader nationally and internationally, building a vast partner network and maintaining technological leadership through continuous R&D in carbon reduction solutions.

By leveraging cutting-edge hydrogen-based and chemical additive technologies, CarbonTech is set to reduce carbon build-up in engines, improve fuel efficiency, and reduce harmful emissions, ultimately enhancing the performance and longevity of automotive parts.

Future Prospects

Carbontech commented, “Our company is uniquely positioned to take advantage of the growing demand for engine decarbonization solutions in Australia. By leveraging cutting-edge technology from Flex Fuel, we can offer businesses and individuals the tools they need to reduce emissions, improve fuel efficiency, and extend the life of their vehicles. With a clear strategy for expansion and a strong commitment to customer satisfaction, we aim to become the leading provider of engine decarbonization services and products in Australia.”

CIDC commented, “We’re pleased to announce our acquisition of Carbontech, marking our entry into the Australian market. This follows the successful reorganization of our JV subsidiary in Shenzhen, which has deployed over 60 hydrogen decarbonizing and cleaning stations have been imported and installed in over 20 locations in China since March. By leveraging Carbontech’s local presence, we will introduce our proven hydrogen injection cleaning technology to help Australian transportation companies reduce emissions, improve fuel efficiency, and extend vehicle lifespan, contributing to a greener Australia.”

About Flex Fuel Hydrogen Development  (Shenzhen) Co., Ltd

The Group and Flex Fuel Hydrogen Development Group Limited was set up a JV company named Flex Fuel Eco Company Limited. By the way of reorganization, the JV company became the holding company of Flex Fuel Hydrogen Development (Shenzhen) Co., Ltd (FFSZ). FFSZ is the exclusive sales and production authorisation of Flex Fuel Energy Development  (Base in France founded in 2009, one of the French technology 120 index companies) Products in Asia-Pacific. The engine hydrogen maintenance equipment has been officially certified by the French Railways Agency, the Oceanic Agency, the Ministry of Environmental Protection and other official safety certifications. At present, the group is engaged in hydrogen research and development and production equipment, providing a full range of energy solutions, applying its equipment and the hydrogen produced according to customer needs, so as to reduce costs, meet the world trend, apply renewable energy, directly reduce emissions and save energy, and meet the requirements of commercial ESG.

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA

CARDIFF-BY-THE-SEA, Calif., April 22, 2025 /PRNewswire/ — Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million in Series A financing. The round includes $20 million in new capital and the conversion of $20 million in seed-round debt. Participants include several leading strategics, venture capital firms and family offices, with multiple seed investors reinvesting – underscoring strong confidence in the company’s initial focus on ventricular tachycardia (VT) and the broader versatility of its technology.

The funding will support the completion of two pilot studies – VCAS for VT and Field PULSE for atrial fibrillation (AF) – as well as continued development of Field’s commercial PFA system and operational scale-up in preparation for VERITAS, the company’s pivotal trial focused on VT.

“This financing is a pivotal milestone as we advance in redefining how electrophysiologists approach ablation therapy,” said Steven Mickelsen, M.D., founder and chief executive officer of Field Medical. “With the support of our investors, we are accelerating the development of the FieldForce™ Ablation System, building on early clinical evidence, and moving closer to our commercial goal of expanding access to next-generation PFA solutions for cardiac ablation.”

“We are encouraged by the strong support and confidence from both new investors and our reinvesting seed-round investor base,” said Oskar Dadason, chief financial officer. “This funding enables us to execute our strategic plan with speed and focus as we transition from early-stage innovation into commercial readiness.”

Field Medical is developing transformative technology for the treatment of all cardiac arrhythmias, including VT and AF. The FieldForce Ablation System, featuring the first built-for-purpose, contact force focal PFA catheter, enables an instantaneous ablation workflow, with therapy delivered in a fraction of a second. Recent results from the VCAS (VT) and PULSE (AF) pilot studies demonstrate the system’s versatility. Powered by FieldBending™, the company’s proprietary technology that delivers brief, high-intensity electric fields, the System is positioned as the single, advanced solution for treating a full spectrum of cardiac arrhythmias.

About Field Medical® Inc.
Founded in 2022, Field Medical is advancing next-generation pulsed field ablation (PFA) technologies to address the complex needs of modern cardiac ablation. The company is led by Dr. Steven Mickelsen, a pioneer in pulsed electric field technology and a leading innovator in the field. His foundational work in PFA established the basis for modern advancements in the technology, which Field Medical continues to refine with its groundbreaking solutions. In 2024, Field Medical’s technology was recognized by the FDA with Breakthrough Device Designation and inclusion in the TAP Pilot Program. 

For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn and X.

The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.

The Growing Prevalence of VT and AF
Ventricular tachycardia (VT) and atrial fibrillation (AF) are two of the most common and serious arrhythmias, contributing to stroke, heart failure, sudden cardiac death and escalating health care costs. VT and premature ventricular contractions (PVCs) affect more than 6 million people in the United States and Europe, while AF impacts an estimated 2% to 6% of the global population.

The AF catheter ablation market is currently valued at $5 billion and is projected to grow at a compound annual growth rate of 13% to 16%, surpassing $11 billion by 2034. In comparison, the global VT market— which includes devices and catheter ablation—was valued at approximately $12.5 billion in 2021 and is expected to grow at a compound annual growth rate of 5.26%, reaching $17 billion by 2027. Notably, the catheter ablation segment within the VT treatment market is projected to grow at a higher rate of 13% annually during this period, reflecting increased adoption of catheter-based interventions for VT management.

Media Contact
Holly Windler
619.929.1275

Logo – https://laotiantimes.com/wp-content/uploads/2025/04/field_medical_logo_block_whiteonblack_logo.jpg 

LOTTE rent-a-car suggests a travel course following the famous scenes from the Netflix Series

‘When Life Gives You Tangerines’

  • LOTTE rent-a-car introduces Jeju travel destinations featured in the drama that captivated global viewers
  • Enhancing convenience for international travelers by providing dedicated staff for foreign customers and multilingual support
  • Offering various services such as chauffeur-driven rental cars, welcome coupon packs, and free electric vehicle charging

SEOUL, South Korea, April 22, 2025 /PRNewswire/ — As the Netflix series ‘When Life Gives You Tangerines’ receives an enthusiastic response from global viewers, interest in Jeju Island, known as the ‘Hawaii of Korea’ and the backdrop of the drama, is increasing. With the peak travel season to Jeju from March to May, the number of foreign tourists looking to experience the unique nature of Jeju depicted in the drama is on the rise.

Jeju Island has many hidden gems that are difficult to access using public transportation alone, making rental cars essential. LOTTE rent-a-car, South Korea’s No.1 rental car brand, holds the top market share in the Korean rental car market and is the official partner of the global rental car brand Hertz, providing verified services. They offer a systematic service system and multilingual support platform for international customers.

LOTTE rent-a-car Jeju Auto House is located near Jeju International Airport. It is the largest single-location rental car facility in the country, with a fleet of 3,000 vehicles. Operating 365 days a year from 6 AM to 11 PM, it allows customers to pick up or return vehicles conveniently regardless of flight times. The proportion of foreign customers renting from LOTTE rent-a-car in Jeju is increasing every year. As of 2024, foreign customers account for 25.6% of the total customers at LOTTE rent-a-car Jeju Auto House, meaning one in four customers is a foreigner.

For international tourists planning a trip to Jeju in the first half of this year, LOTTE rent-a-car suggests a special Jeju travel course centered around the filming locations of iconic scenes from the drama. These include Gimnyeong Beach, where young Aesoon eagerly waited for her mother, and Seongsan Ilchulbong, which showcases the beautiful scenery of Jeju.

Gimnyeong Beach: A Pristine Beach Embodying the Lives of female divers

Located in eastern Jeju, Gimnyeong Beach gained attention as the setting for the lives of haenyeo(female divers) in the drama. The exotic landscape, where cobalt blue waters, white sandy beaches, and black basalt rocks harmonize, leaves visitors in awe. Not only can visitors experience the local haenyeo culture, but they can also enjoy various marine activities such as yachting, kayaking, and snorkeling. The walking trail along the wind turbines lined up on the eastern side of the beach and the nearby cave exploration course add a unique charm.

Seongsan Ilchulbong: A UNESCO World Heritage Site and Sunrise Spot

Seongsan Ilchulbong, where the protagonist Aesoon performs 3,000 bows in the drama, is one of Jeju’s most iconic natural landmarks. Formed by underwater volcanic activity about 5,000 years ago, its cratered terrain is notable. This site is recognized as a UNESCO World Natural Heritage due to its geological significance and is also famous for its breathtaking sunrise views over the open sea. The magnificent scenery, where the blue sea and cliffs blend, leaves a lasting impression on both drama fans and general tourists.

Ora-dong Buckwheat Field: A Healing Photo Spot with Different Faces Each Season

The buckwheat flower path where Aesoon and Gwansik shared memories in the drama was filmed in the buckwheat fields of Ora-dong, Jeju City. The vast field, equivalent to 130 soccer fields, offers different charms each season, making it an ideal photo spot, especially for wedding photos. In spring, yellow canola flowers, in summer, pure white buckwheat flowers adorn the field, and from late winter to spring, the landscape is filled with green barley and reeds. May and June are the best times to witness the most splendid scenery.

Jejumok Gwana: Where Aesoon and Gwansik Wrote Poems for the Writing Contest

Jejumok Gwana is where the writing contest in the drama took place. It was the administrative center of Jeju during the Joseon Dynasty and is a nationally designated heritage site and a representative historical and cultural tourist attraction in Jeju. Aesoon and Gwansik sat in front of Yeonhuijeong Pavilion in this Gwana to write poems. It is also the place where the middle-aged Aesoon wrote a poem longing for her mother. Recently, it has become very popular among foreign tourists, as they can rent hanbok(traditional Korean clothing) from nearby rental shops. It is common to see tourists taking photos in hanbok in front of the traditional Korean houses.

LOTTE rent-a-car Welcomes Foreign Customers with Professional Staff, Coupon Packs, and Electric Vehicle Promotions

LOTTE rent-a-car operates professional staff who can provide consultations in foreign languages. The official website supports English, Chinese, and Japanese, allowing international customers to smoothly handle the entire process from vehicle reservation to contract management and consultation in their native language. This makes it easy for first-time visitors to Korea to use the rental car service.

For tourists who find driving on unfamiliar roads burdensome or have a lot of luggage, it is recommended to use the chauffeur service. Professional drivers familiar with the local road conditions will drive, allowing tourists to focus solely on the beautiful scenery of Jeju outside the window. A variety of vehicle types are available, from compact cars to vans, SUVs, and 11-seater and 15-seater vehicles. This service can be used upon reservation inquiry.

There are also various benefits provided to international tourists using LOTTE rent-a-car. The ‘Jeju Welcome Coupon Pack,’ which consists of benefits necessary for traveling in Jeju, is a new free service offered to customers using LOTTE rent-a-car’s short-term rental cars in Jeju. It provides discounts of up to 54% on popular tourist attractions in Jeju and LOTTE affiliates. A free charging promotion that provides a charging card for electric vehicle users is also being implemented for international customers. Jeju’s major tourist attractions are well-equipped with electric vehicle charging infrastructure, making it convenient to use electric vehicles.

LOTTE rental, stated, “We will continue to expand various customized services so that travelers from around the world can experience the beauty and sentiment of Jeju more conveniently,” adding, “LOTTE rent-a-car will continue to enhance trust and satisfaction as a brand that accompanies the journeys of global customers.”

LOTTE rental is South Korea’s leading rental company, providing integrated rental solutions across all fields, including automobiles, office automation equipment and industrial equipment. Its subsidiary, LOTTE rent-a-car, holds the top market share in the domestic rental car industry and offers extensive mobility services to domestic and international customers through over 220 branches nationwide and a global partnership network. 

https://www.lotterentacar.net/hp/chn/reservation/index.do?LANG=chn 

Everest Medicines Announces Approval of “B” Marker Removal from Company’s Stock Code by the Hong Kong Stock Exchange

SHANGHAI, April 22, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has approved the Company’s application to remove the “B” marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange.

“We are very pleased that Everest Medicines has satisfied the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules and successfully removed the ‘B’ marker – a significant milestone for the Company in the capital markets that could lead to wider investor participation.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Moving forward, we will continue to deepen our ‘dual-engine strategy’, enhancing our commercial excellence and advance our first-in-class and best-in-class assets with global rights to maximize synergies. With global rights to EVER001, we will actively explore partnership opportunities outside of China to leverage international expertise and optimize commercial value, while further enhancing Everest’s global visibility and presence. Everest will leverage its established efficient commercial platform to solidify our position in key therapeutic areas, advance innovation on our mRNA platform, and strive to become a leading biopharma in the Asia-Pacific region by 2030.

The removal of the “B” marker reflects a comprehensive evaluation of Everest Medicines’ robust R&D pipeline, commercialization capabilities, and overall business fundamentals. Listed on the Stock Exchange in October 2020, Everest has adopted a “dual-engine” strategy, focusing on high-value therapeutic areas while striving to develop first-in-class or best-in-class innovative treatments. The company has established a strong and synergistic platform across nephrology, infectious diseases, and autoimmune diseases, with three commercialized products already driving rapid revenue growth.

According to the company’s 2024 financial results, total revenue reached RMB706.7 million, representing a 461% year-over-year increase and exceeding our revenue guidance of RMB700 million, and achieved commercial-level profitability for the full year of 2024.

NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s National Reimbursement Drug List (NRDL), effective January 1, 2025.

As the first-in-class fluorocycline antibiotic, XERAVA® (eravacycline) maintained robust growth with generated RMB352.8 million in revenue in 2024, representing a 256% year-on-year increase.

VELSIPITY® (etrasimod), a best-in-class therapy for autoimmune diseases, has been received regulatory approvals in Macau and Singapore, the product was subsequently commercially launched in December in Guangdong province under the “Hong Kong and Macau Medicine and Equipment Connect” policy. In parallel, New Drug Applications (NDAs) for VELSIPITY® have been officially accepted in both mainland China and Hong Kong in December 2024.

EVER001, for which Everest holds global rights, delivered positive results from the preliminary analysis of our Phase 1b/2a trial and is progressing steadily through global development. EVM16, our personalized therapeutic mRNA cancer vaccine, completed first patient dosing in an investigator-initiated clinical trial (IIT) in March 2025. EVM14, our off-the-shelf tumor-associated antigen (TAA) vaccine, received Investigational New Drug (IND) approval from the U.S. FDA, and we plan to submit an IND application to China’s NMPA in the first half of this year. The in vivo CAR-T program is expected to achieve preclinical candidate milestone later this year. These programs are supported by our commercial-scale, GMP-compliant manufacturing facility in Jiashan, Zhejiang, which provides integrated R&D, production, and commercialization capabilities across mRNA and other pipeline platforms. 

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

LoveStudy AI Launches AI-Powered Flashcard, Quiz & Notes Tool to Cut Study Time in Half

SHERIDAN, Wyo., April 22, 2025 /PRNewswire/ — LoveStudy AI, an innovative online learning platform, officially launches today, empowering students worldwide to study smarter, not harder.

Combining cutting-edge AI technology with cognitive science principles, LoveStudy AI transforms traditional study methods into personalized, efficient, and engaging learning experiences that adapt to each student’s unique needs.

The Future of Learning Has Arrived

In today’s fast-paced academic environment, students grapple with information overload, inefficient study techniques, and dwindling motivation. LoveStudy AI addresses these challenges through its three revolutionary AI-powered features:

1. One-Click Flashcards That Enhance Retention

Instantly transforms textbooks, notes, and PDFs into optimized flashcards.

Uses spaced repetition algorithms timed to combat forgetting.

2. Weakness-Targeting Quizzes That Accelerate Mastery

Automatically generates tests focusing on knowledge gaps.

Adapts difficulty in real-time like a personal tutor.

3. Smart Notes That Distill Knowledge

Extracts key concepts from lengthy chapters in seconds.

Highlights connections between ideas missed by human readers.

“We exist to support overwhelmed students—transforming stressful learning into an efficient, even enjoyable journey,” says Jeffrey Jou, CEO of LoveStudy AI.

Special Launch Promotion

To celebrate its official debut, LoveStudy AI is offering 30 Free Credits to the first 1,000 registered users.

This limited-time offer grants full access to all premium features, including:

Unlimited AI flashcard generation
Advanced quiz customization
Priority customer support

Claim at: https://lovestudy.ai/

About LoveStudy AI

Founded in 2025 and headquartered in the United States, LoveStudy AI represents the next evolution in educational technology.

This innovative suite is designed to reduce average study time by 53% while improving test scores for 87% of beta users, making it one of the most useful and convenient online AI learning tools available today.

Media Contact:
Lisa Brown
PR Manager, LoveStudy AI
Phone: +1 307 533 2034
Email: support@lovestudy.ai

Azazie Makes a Statement at London’s National Wedding Show with Bold Bridal Looks and the UK’s Largest Pop-Up Experience

LONDON, April 22, 2025 /PRNewswire/ — This April, Azazie, the global leader in online bridalwear, made an unforgettable impression at The National Wedding Show at ExCeL London. Located at Stand D70, the brand unveiled its most expansive UK presentation to date—a thoughtfully curated bridalwear collection celebrating inclusivity, modern romance, and personal expression. The showcase offered attendees an exclusive first look at Azazie’s highly anticipated London Pop-Up, alongside a glimpse into the wedding trends set to define 2025.

Breaking Tradition, Embracing Individuality

Azazie redefined what bridal looks like in 2025. Across six high-energy catwalk shows, the brand debuted everything from sweeping fairytale gowns to clean-cut modern silhouettes, tailored bridal pantsuits, and bridesmaid dresses in vibrant hues. This season’s focus? Celebrating self-expression. Every look was designed with today’s bride in mind.

The Pop-Up Everyone’s Talking About

Visitors were given an exclusive first look—and first access—to Azazie’s 2-Day London Pop-Up, happening April 19–20. With over 750 garments available to try on, it’s the largest single-location preview Azazie has ever hosted in the UK. Highlights include:

  • 500+ Bridesmaid Dresses in 80+ colours and sizes 4–34
  • 150 Wedding Dresses ranging from timeless lace to daring fashion-forward cuts
  • 25 Flower Girl Dresses

  • 25 Junior Bridesmaid Looks

  • 25 Mother-of-the-Bride Dresses

  • 25 Occasionwear Styles, perfect for black-tie guests or second looks

With just a quick QR scan, brides secured their personalised fitting appointments—complete with expert stylists and on-the-spot advice for curating their wedding wardrobe with ease.

Not Just a Booth—An Experience

Azazie went beyond the typical vendor setup and built an immersive showroom-style space, where guests could slip into gowns, explore fabric swatches, and chat directly with the team about fit, customisation, and the perks of Azazie’s seamless online shopping experience.

Fan-favourite Spin-to-Win returned, offering prizes like stretch satin scrunchies, wedding garters, jewellery boxes, and 10% off vouchers—adding a little extra sparkle to every visit.

Expanding Its Footprint in the UK

Following a successful showing in Birmingham, Azazie’s London debut drew thousands of visitors, including entire bridal parties discovering the brand’s affordable, size-inclusive, made-to-order model for the very first time.

With a growing UK presence and increasing demand, Azazie is solidifying its role as the go-to destination for modern brides who want standout style without the boutique markup.

Ready to Say Yes?

To learn more about Azazie’s full UK offering or to book your spot at the upcoming London Pop-Up, visit www.azazie.com.

ABOUT AZAZIE

Azazie is the leading direct-to-consumer (DTC) e-tailer, providing an array of bridal gowns, bridesmaid dresses, evening wear, and accessories. Designed in Los Angeles, Azazie disrupts the traditional wedding industry by offering made-to-order gowns at an affordable price point. The brand is dedicated to promoting body-positive fashion, ensuring that all dresses—available in sizes 0-30—are meticulously cut and sewn to order. Explore our website to discover hundreds of bridal and bridesmaid gowns and dresses in over 80+ stunning color options.

Media Contact:

pr@azazie.com 

NAVER D2SF Invests in Virtual IP and Content Startup “SCON”

– Possesses specialized content planning and production capabilities for virtual IP … Currently pursuing both IP development/planning and B2B solutions business
– Has debuted the largest number of virtual characters in Korea based on strong technical expertise and industry know-how
– Expects synergy with NAVER’s virtual teams, such as CHZZK and Motion Stage

SEOUL, South Korea, April 21, 2025 /PRNewswire/ — NAVER D2SF has made a new investment in “SCON”, a startup specializing in virtual IP and content. SCON provides B2B solutions tailored for virtual content production while planning and managing its own virtual IP and content using such solutions.

SCON has developed specialized solutions for virtual content production and distribution, such as 3D motion capture and live streaming, and has offered them as B2B services to various IP companies, including webtoon and gaming. In line with the characteristics of virtual content, where active user interaction is important, these solutions have improved the efficiency of real-time content production. The company also operates its own studio, a distinct feature that ensures the stable delivery of high-quality content.

In addition, SCON is also building a strong presence in virtual IP and content planning and management using its proprietary solutions. Since its founding, the company has debuted the largest number of virtual characters in South Korea and currently manages around 30 virtual character IPs, including the VTuber group “Meechu.” Based on these IPs, they generate revenue through live stream donations, merchandise, and advertising.

Yang Sang-hwan, Head of NAVER D2SF, said, “SCON is a rare team that combines both planning and technical capabilities in the virtual industry. Their know-how in IP development and planning, paired with robust content production solutions, gives them a clear competitive edge.” He added, “They are already closely collaborating with NAVER’s virtual technology and business organizations, and we expect to create synergies across various touchpoints in the future.”

Gi-Junsu, CEO of SCON, stated, “we plan to expand our revenue streams by developing secondary content—such as games, music, and web novels—based on various virtual IPs, creating more diverse monetization opportunities for virtual creators. We will also continue to enhance our technology to ensure the stable production of high-quality virtual live content.”

Recently, NAVER has been enhancing its virtual technology and content experience by officially launching “Motion Stage”, a dedicated motion capture studio for virtual content. Since 2021, NAVER D2SF has been making proactive investments across the virtual technology spectrum, including 3D engines, data, and content creation, while supporting exchanges and cooperation with relevant NAVER virtual teams. “MOVIN”, 3D real-time motion capture startup; “NdotLight”, 3D engine technology startup; and “Claythis”, 3D generation AI startup, are prime examples. 

About NAVER D2SF

NAVER D2SF is NAVER’s corporate venturing(CV) arm, taking on greater challenges and fostering more sustainable growth through collaboration with startups. Founded in 1999, NAVER is a rare example of a domestic search engine that has maintained its top position in South Korea for over 20 years and has established a strong presence in various business sectors including commerce, content, fintech, and cloud services. In addition to its own offerings, NAVER is building a strong global business portfolio through partnerships with industry-leading companies, including Softbank, Poshmark, and Wattpad. At the same time, under the technological vision of D2(For Developers, By Developers), we are actively developing new technologies and collaboration initiatives to grow into a global tech company.

To learn more, visit  https://d2sf.naver.com/en